Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Endocrinological Investigation
Published in: Journal of Endocrinological Investigation 11/2017

01-11-2017 | Review

Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options

Authors: A. A. Verhaegen, L. F. Van Gaal

Published in: Journal of Endocrinological Investigation | Issue 11/2017

Login to get access

Abstract

Weight gain is a common side effect of many widely used drugs. Weight gain of a few kilograms to an increase of 10% or more of initial body weight has been described. Not only the weight gain as such puts a burden on the health risks of the involved patients, the accompanying increase in the incidence of the metabolic syndrome, type 2 diabetes mellitus, and cardiovascular risk factors urges the caregiver to identify and to closely monitor the patients at risk. In this review, the different classes of drugs with significant weight gaining properties and the metabolic consequences are described. Specific attention is given to pathogenetic mechanisms underlying the metabolic effects and to potential therapeutic measures to prevent them.
Literature
1.
2.
Medici V, McClave SA, Miller KR (2016) Common medications which lead to unintended alterations in weight gain or organ lipotoxicity. Curr Gastroenterol Rep 18(1):2–12CrossRefPubMed
3.
Domecq JP, Prutsky Gk KF, Lababidi MH et al (2015) Drugs commonly associated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab 100(2):363–370CrossRefPubMedPubMedCentral
4.
Curtis JR, Westfall AO, Allison J et al (2006) Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 55(3):420–426CrossRefPubMed
5.
Wung PK, Anderson T, Fontaine KR et al (2008) Effects of glucocorticoids on weight change during the treatment of Wegener’s granulomatosis. Wegener’s Granulomatosis Etanercept Trial Research Group. Arthritis Rheum 59(5):746–753CrossRefPubMedPubMedCentral
6.
Elster EA, Leeser DB, Morrissette C et al (2008) Obesity following kidney transplantation and steroid avoidance immunosuppression. Clin Transplant 22(3):354–359CrossRefPubMed
7.
Christ-Crain M, Kola B, Lolli F, Fekete C, Seboek D, Wittmann G et al (2008) AMP-activated protein kinase mediates glucocorticoid induced metabolic changes: a novel mechanism in Cushing’s syndrome. FASEB J 22:1672–1683CrossRefPubMed
8.
Bowles NP, Karatsoreos IN, Li X et al (2015) A peripheral endocannabinoid mechanism contributes to glucocorticoid-mediated metabolic syndrome. Proc Natl Acad Sci USA 112(1):285–290CrossRefPubMed
9.
Petersons CJ, Mangelsdorf BL, Jenkins AB et al (2013) Effects of low-dose prednisolone on hepatic and peripheral insulin sensitivity, insulin secretion, and abdominal adiposity in patients with inflammatory rheumatologic disease. Diabetes Care 36:2822–2829CrossRefPubMedPubMedCentral
10.
Dube S, Slama MQ, Basu A, Rizza RA, Basu R (2015) Glucocorticoid excess increases hepatic 11β-HSD-1 activity in humans: implications in steroid-induced diabetes. J Clin Endocrinol Metab 100(11):4155–4162CrossRefPubMedPubMedCentral
11.
Wolf G (2002) Glucocorticoids in adipocytes stimulate visceral obesity. Nutr Rev 60(5 Pt 1):148–151PubMed
12.
Stomby A, Andrew R, Walker BR, Olsson T (2014) Tissue-specific dysregulation of cortisol regeneration by 11betaHSD1 in obesity: has it promised too much? Diabetologia 57(6):1100–1110CrossRefPubMed
13.
Van Gaal L, Scheen A (2015) Weight management in type 2 diabetes: current and emerging approaches to treatment. Diabetes Care 38(6):1161–1172CrossRefPubMed
14.
Russell-Jones D, Khan R (2007) Insulin-associated weight gain in diabetes—causes, effects and coping strategies. Diabetes Obes Metab 6:799–812CrossRef
15.
Pontiroli AE, Miele L, Morabito A (2011) Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis. Diabetes Obes Metab 13(11):1008–1019CrossRefPubMed
16.
Mäkimattila S, Nikkilä K, Yki-Yärvinen H (1999) Causes of weight gain during insulin therapy with and without metformin in patients with type 2 diabetes mellitus. Diabetologia 42:406–412CrossRefPubMed
17.
Hermansen K, Davies M (2007) Does insulin detemir have a role in reducing risk of insulin-associated weight gain? Diabetes Obes Metab 9(3):209–217CrossRefPubMed
18.
UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854–865CrossRef
19.
Kahn SE, Haffner SM, Heise MA, F.R.C.P. for the ADOPT Study Group et al (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427–2443CrossRefPubMed
20.
Wilding J (2006) Thiazolidinediones, insulin resistance and obesity: finding a balance. Int J Clin Pract 60:1272–1280CrossRefPubMed
21.
22.
UK Prospective Diabetes Study Group (1995) Overview of 6 years’ therapy of type II diabetes: a progressive disease (UK prospective diabetes study 16). Diabetes 44:149–158CrossRef
23.
Apovian CM, Aronne LJ, Bessesen DH et al (2015) Pharmacological management of obesity: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab 100(2):342–362CrossRefPubMed
24.
Landsberg L, Aronne LJ, Beilin LJ, Burke V, Igel LI, Lloyd-Jones D, Sowers J (2013) Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment—a position paper of The Obesity Society and The American Society of Hypertension. Obesity (Silver Spring) 21(1):8–24CrossRef
25.
Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC (2001) B-adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension 37:250–254CrossRefPubMed
26.
Messerli FH, Bell DS, Fonseca V, Investigators GEMINI et al (2007) Body weight changes with beta-blocker use: results of GEMINI. Am J Med 120(7):610–615CrossRefPubMed
27.
Clement K, Vaisse C, Manning BS et al (1995) Genetic variation in the beta 3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity. N Engl J Med 333:352–354CrossRefPubMed
28.
Welle S, Schwartz RG, Statt M (1991) Reduced metabolic rate during beta-adrenergic blockade in humans. Metabolism 40:619–622CrossRefPubMed
29.
Astrup A, Simonsen L, Bülow J, Madsen J, Christensen NJ (1989) Epinephrine mediates facultative carbohydrate-induced thermogenesis in human skeletal muscle. Am J Physiol 257(3 Pt 1):E340–E345PubMed
30.
Koch G, Franz IW, Lohmann FW (1981) Effects of short-term and long-term treatment with cardio-selective and non-selective beta-receptor blockade on carbohydrate and lipid metabolism and on plasma catecholamines at rest and during exercise. Clin Sci 61(suppl 7):433s–435sCrossRefPubMed
31.
Elliott WJ, Meyer PM (2007) Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369(9557):201–207CrossRefPubMed
32.
Pollare T, Lithell H, Selinus I, Berne C (1989) Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ 298(6681):1152–1157CrossRefPubMedPubMedCentral
33.
Bakris GL, Fonseca V, Katholi RE, Investigators GEMINI et al (2004) Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 292(18):2227–2236CrossRefPubMed
34.
Ripley TL, Saseen JJ (2014) β-blockers: a review of their pharmacological and physiological diversity in hypertension. Ann Pharmacother 48(6):723–733CrossRefPubMed
35.
Moore TJ, Mattison DR (2017) Adult utilization of psychiatric drugs and differences by sex, age, and race. JAMA Intern Med 177(2):274–275CrossRefPubMed
36.
Compton MT, Daumit GL, Druss BG (2006) Cigarette smoking and overweight/obesity among individuals with serious mental illnesses: a preventive perspective. Harv Rev Psychiatry 14(4):212–222CrossRefPubMed
37.
Naughton M, Dinan TG, Scott LV (2014) Corticotropin-releasing hormone and the hypothalamic-pituitary-adrenal axis in psychiatric disease. Handb Clin Neurol 124:69–91CrossRefPubMed
38.
Ménard C, Pfau ML, Hodes GE, Russo SJ (2017) Immune and neuroendocrine mechanisms of stress vulnerability and resilience. Neuropsychopharmacology 42(1):62–80CrossRefPubMed
39.
Capuron L, Lasselin J, Castanon N (2017) Role of adiposity-driven inflammation in depressive morbidity. Neuropsychopharmacology 42(1):115–128CrossRefPubMed
40.
Chuang JC, Krishnan V, Yu HG et al (2010) A beta3-adrenergic-leptin-melanocortin circuit regulates behavioral and metabolic changes induced by chronic stress. Biol Psychiatry 67(11):1075–1082CrossRefPubMedPubMedCentral
41.
Zimmermann U, Kraus T, Himmerich H, Schuld A, Pollmächer T (2003) Epidemiology, implications and mechanisms underlying drug induced weight gain in psychiatric patients. J Psychiatr Res 37(3):193–220CrossRefPubMed
42.
Vandenberghe F, Gholam-Rezaee M, Saigí-Morgui N et al (2015) Importance of early weight changes to predict long-term weight gain during psychotropic drug treatment. J Clin Psychiatry 76(11):e1417–e1423CrossRefPubMed
43.
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists et al (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27(2):596–601CrossRef
44.
45.
Smith GC, Vickers MH, Cognard E, Shepherd PR (2009) Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: implications for glucose metabolism and food choice behaviour. Schizophr Res 115(1):30–40CrossRefPubMed
46.
47.
Himmerich H, Minkwitz J, Kirkby KC (2015) Weight gain and metabolic changes during treatment with antipsychotics and antidepressants. Endocr Metab Immune Disord Drug Targets 15(4):252–260CrossRefPubMed
48.
Casey DE, Zorn SH (2001) The pharmacology of weight gain with antipsychotics. Clin Psych 62(suppl 7):4–10
49.
Bahra SM, Weidemann BJ, Castro AN et al (2015) Risperidone-induced weight gain is mediated through shifts in the gut microbiome and suppression of energy expenditure. EBioMedicine 2(11):1725–1734CrossRefPubMed
50.
Oh JE, Cho YM, Kwak SN et al (2012) Inhibition of mouse brown adipocyte differentiation by second-generation antipsychotics. Exp Mol Med 44(9):545–553CrossRefPubMedPubMedCentral
51.
Pavan C, Vindigni V, Michelotto L et al (2010) Weight gain related to treatment with atypical antipsychotics is due to activation of PKC-β. Pharmacogenomics J 10(5):408–417CrossRefPubMed
52.
Everard A, Cani PD (2013) Diabetes, obesity and gut microbiota. Best Pract Res Clin Gastroenterol 27(1):73–83CrossRefPubMed
53.
Flowers SA, Evans SJ, Ward KM, McInnis MG, Ellingrod VL (2017) Interaction between atypical antipsychotics and the gut microbiome in a bipolar disease cohort. Pharmacotherapy 37(3):261–267CrossRefPubMed
54.
Shams TA, Müller DJ (2014) Antipsychotic induced weight gain: genetics, epigenetics, and biomarkers reviewed. Curr Psychiatry Rep 16(10):473CrossRefPubMed
55.
Lett TA, Wallace TJ, Chowdhury NI, Tiwari AK, Kennedy JL, Müller DJ (2012) Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Mol Psychiatry 17(3):242–266CrossRefPubMed
56.
Serreti A, Mandelli L (2010) Antidepresants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 71(10):1259–1272CrossRef
57.
Massand PS, Gupta S (2002) Long term side effects of newer generation antidepressants SSRIS, venlafaxine, nefazodone, bupropion and mirtazapine. Ann Clin Psychiatry 14(3):175–182CrossRef
58.
59.
Billes SK, Sinnayah P, Cowley MA (2014) Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. Pharmacol Res 84:1–11CrossRefPubMed
60.
Livingstone C, Rampes H (2006) Lithium: a review of its metabolic adverse effects. J Psychopharmacol 20(3):347–355CrossRefPubMed
61.
62.
Sohn M, Moga DC, Blumenschein K, Talbert J (2016) National trends in off-label use of atypical antipsychotics in children and adolescents in the United States. Medicine (Baltimore) 95(23):e3784CrossRef
63.
Verdoux H, Tournier M, Bégaud B (2010) Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies. Acta Psychiatr Scand 121(1):4–10CrossRefPubMed
64.
Allison DB, Mentore JL, Heo M et al (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156(11):1686–1696PubMed
65.
Allison DB, Casey DE (2001) Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 62(Suppl 7):22–31PubMed
66.
Balf G, Stewart DT, Whitehead R, Baker RA (2008) Metabolic adverse events in patients with mental illness treated with antipsychotics: a primary care perspective. Prim Care Companion J Clin Psychiatry 10(1):15–24CrossRefPubMedPubMedCentral
67.
Orsolini L, Tomasetti C, Valchera A et al (2016) An update of safety of clinically used atypical antipsychotics. Expert Opin Drug Saf 15(10):1329–1347CrossRefPubMed
68.
Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK (2009) Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 302(16):1765–1773CrossRefPubMedPubMedCentral
69.
Hoffmann VP, Case M, Stauffer VL, Jacobson JG, Conley RR (2010) Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, controlled trials. J Clin Psychopharmacol 30(6):656–660CrossRefPubMed
70.
Ascher-Svanum H, Stensland M, Zhao Z, Kinon BJ (2005) Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia. BMC Psychiatry 5:3CrossRefPubMedPubMedCentral
71.
Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M (2013) Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders—a systematic review and meta-analysis. Schizophr Bull 39(2):306–318CrossRefPubMed
72.
Holt RI, Peveler RC (2006) Association between antipsychotic drugs and diabetes. Diabetes Obes Metab 8(2):125–135CrossRefPubMed
73.
De Hert M, Detraux J, van Winkel R, Yu W, Correll CU (2011) Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 8(2):114–126CrossRefPubMed
74.
Ballon JS, Pajvani U, Freyberg Z, Leibel RL, Lieberman JA (2014) Molecular pathophysiology of metabolic effects of antipsychotic medications. Trends Endocrinol Metab 25(11):593–600CrossRefPubMed
75.
Dwyer DS, Donohoe D (2003) Induction of hyperglycemia in mice with atypical antipsychotic drugs that inhibit glucose uptake. Pharmacol Biochem Behav 75(2):255–260CrossRefPubMed
76.
Daumit GL, Goff DC, Meyer JM et al (2008) Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res 105(1–3):175–187CrossRefPubMedPubMedCentral
77.
Ben-Menachem E (2007) Weight issues for people with epilepsy—a review. Epilepsia 48(Suppl 9):42–45CrossRefPubMed
78.
Verrotti A, D’Egidio C, Mohn A, Coppola G, Chiarelli F (2011) Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications. Obes Rev 12(5):e32–e43CrossRefPubMed
79.
Belcastro V, D’Egidio C, Striano P, Verrotti A (2013) Metabolic and endocrine effects of valproic acid chronic treatment. Epilepsy Res 107(1–2):1–8CrossRefPubMed
80.
Wong HY, Chu TS, Lai JC et al (2005) Sodium valproate inhibits glucose transport and exacerbates Glut1-deficiency in vitro. J Cell Biochem 96(4):775–785CrossRefPubMed
81.
Farinelli E, Giampaoli D, Cenciarini A, Cercado E, Verrotti A (2015) Valproic acid and nonalcoholic fatty liver disease: a possible association? World J Hepatol 7(9):1251–1257CrossRefPubMedPubMedCentral
82.
Swann AC (2001) Major system toxicities and side effects of anticonvulsants. J Clin Psychiatry 62(suppl 14):16–21PubMed
83.
Antel J, Hebebrand J (2012) Weight-reducing side effects of the antiepileptic agents topiramate and zonisamide. Handb Exp Pharmacol 209:433–466CrossRef
84.
Smith SM, Meyer M, Trinkley KE (2013) Phentermine/topiramate for the treatment of obesity. Ann Pharmacother 47(3):340–349CrossRefPubMed
85.
Gierisch JM, Nieuwsma JA, Bradford DW et al (2013) Interventions to improve cardiovascular risk factors in people with serious mental illness [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US). Report No.: 13-EHC063-EF. AHRQ Comparative Effectiveness Reviews
86.
Green CA, Yarborough BJ, Leo MC et al (2015) The STRIDE weight loss and lifestyle intervention for individuals taking antipsychotic medications: a randomized trial. Obesity (Silver Spring) 23(10):1995–2001CrossRef
87.
Alvarez-Jiménez M, Hetrick SE, González-Blanch C, Gleeson JF, McGorry PD (2008) Non pharmacological management of antipsychotic-induced weight gain: systematic review and meta analysis of randomised controlled trials. Br J Psychiatry 193(2):101–107CrossRefPubMed
88.
Newcomer JW, Weiden PJ, Buchanan RW (2013) Switching antipsychotic medications to reduce adverse event burden in schizophrenia: establishing evidence-based practice. J Clin Psychiatry 74(11):1108–1120CrossRefPubMed
89.
Hasnain M, Vieweg WV (2013) Weight considerations in psychotropic drug prescribing and switching. Postgrad Med 125(5):117–129CrossRefPubMed
90.
Mukundan A, Faulkner G, Cohn T, Remington G (2010) Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database Syst Rev (12):CD006629. doi:10.​1002/​14651858.​CD006629.​pub2
91.
Mizuno Y, Suzuki T, Nakagawa A et al (2014) Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull 40(6):1385–1403CrossRefPubMedPubMedCentral
92.
Zheng W, Li XB, Tang YL, Xiang YQ, Wang CY, de Leon J (2015) Metformin for weight gain and metabolic abnormalities associated with antipsychotic treatment: meta-analysis of randomized placebo-controlled trials. J Clin Psychopharmacol 35(5):499–509CrossRefPubMed
93.
94.
Ebdrup BH, Knop FK, Ishøy PL et al (2012) Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits. BMC Med 10:92CrossRefPubMedPubMedCentral
95.
Lykkegaard K, Larsen PJ, Vrang N, Bock C, Bock T, Knudsen LB (2008) The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance. Schizophr Res 103(1–3):94–103CrossRefPubMed
96.
Sharma AN, Ligade SS, Sharma JN, Shukla P, Elased KM, Lucot JB (2015) GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats. Metab Brain Dis 30(2):519–527CrossRefPubMed
97.
Larsen JR, Vedtofte L, Jakobsen MSL et al (2017) Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine-or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial. JAMA Psychiatry. doi:10.​1001/​jamapsychiatry.​2017.​1220 PubMed
98.
Müller N (2010) COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence. Curr Opin Investig Drugs 11(1):31–42PubMed
99.
Gross C, Blasey CM, Roe RL, Belanoff JK (2010) Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men. Obesity (Silver Spring.) 18(12):2295–2300CrossRef
100.
Belanoff JK, Blasey CM, Clark RD, Roe RL (2010) Selective glucocorticoid receptor (type II) antagonist prevents and reverses olanzapine-induced weight gain. Diabetes Obes Metab 12(6):545–547CrossRefPubMed
101.
Rimessi A, Pavan C, Ioannidi E et al (2017) Protein kinase C β: a new target therapy to prevent the long-term atypical antipsychotic-induced weight gain. Neuropsychopharmacology 42(7):1491–1501CrossRefPubMed
Metadata
Title
Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options
Authors
A. A. Verhaegen
L. F. Van Gaal
Publication date
01-11-2017
Publisher
Springer International Publishing
Published in
Journal of Endocrinological Investigation / Issue 11/2017
Electronic ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-017-0719-6

Other articles of this Issue 11/2017

Journal of Endocrinological Investigation 11/2017 Go to the issue

Original Article

Fluid intelligence, traits of personality and personality disorders in a cohort of adult KS patients with the classic 47, XXY karyotype

Original Article

Associations of blood glucose dynamics with antihyperglycemic treatment and glycemic variability in type 1 and type 2 diabetes

Original Article

Benefits of a regular vs irregular rhythm-based training programme on physical fitness and motor skills in obese girls

Original Article

Chronic prostatitis and its detrimental impact on sperm parameters: a systematic review and meta-analysis

Original Article

Levothyroxine monotherapy versus levothyroxine and selenium combination therapy in chronic lymphocytic thyroiditis

Letter to the Editor

Acquired partial lipodystrophy after bone marrow transplant during childhood: a novel syndrome to be added to the disease classification list
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits